Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. 1998

A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
INSERM Unité 481 and Centre de Recherche sur les Hépatites Virales (Association Claude Bernard), Hôpital Beaujon, Clichy, France.

OBJECTIVE 4,4'-Diethylaminoethoxyhexestrol (DEAEH), amiodarone, and perhexiline cause steatohepatitis in humans. The mechanisms of these effects are unknown for DEAEH and have not been completely elucidated for amiodarone and perhexiline. The aim of this study was to determine these mechanisms. METHODS Rat liver mitochondria, cultured rat hepatocytes, or rats were treated with these drugs, and the effects on mitochondrial respiration, beta-oxidation, reactive oxygen species formation, and lipid peroxidation were determined. RESULTS DEAEH accumulated in mitochondria and inhibited carnitine palmitoyl transferase I and acyl-coenzyme A dehydrogenases; it decreased beta-oxidation and caused lipid deposits in hepatocytes. DEAEH also inhibited mitochondrial respiration and decreased adenosine triphosphate (ATP) levels in hepatocytes. DEAEH, amiodarone, and perhexiline augmented the mitochondrial formation of reactive oxygen species and caused lipid peroxidation in rats. CONCLUSIONS Like amiodarone and perhexiline, DEAEH accumulates in mitochondria, where it inhibits both beta-oxidation (causing steatosis) and respiration. Inhibition of respiration decreases ATP and also increases the mitochondrial formation of reactive oxygen species. The latter oxidize fat deposits, causing lipid peroxidation. We suggest that ATP depletion and lipid peroxidation may cause cell death and that lipid peroxidation products may account, in part, for other steatohepatitis lesions.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008930 Mitochondria, Liver Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4) Liver Mitochondria,Liver Mitochondrion,Mitochondrion, Liver
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005234 Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. Liver Steatosis,Steatohepatitis,Steatosis of Liver,Visceral Steatosis,Liver Steatoses,Liver, Fatty,Steatohepatitides,Steatoses, Liver,Steatoses, Visceral,Steatosis, Liver,Steatosis, Visceral,Visceral Steatoses
D006589 Hexestrol A synthetic estrogen that has been used as a hormonal antineoplastic agent. Dihydrodiethylstilbestrol,Hexestrol, (R*,R*)-(+-)-Isomer,Hexestrol, (R*,S*)-Isomer,Hexestrol, (R-(R*,R*))-Isomer,Hexestrol, (S-(R*,R*))-Isomer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
September 1986, Toxicology,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
January 1997, Journal of hepatology,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
May 1980, Toxicology and applied pharmacology,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
January 2002, Blood cells, molecules & diseases,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
December 1983, Chemico-biological interactions,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
January 1998, Proceedings of the National Academy of Sciences of the United States of America,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
August 2004, Toxicology,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
April 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
January 1975, European journal of biochemistry,
A Berson, and V De Beco, and P Lettéron, and M A Robin, and C Moreau, and J El Kahwaji, and N Verthier, and G Feldmann, and B Fromenty, and D Pessayre
July 2015, Brain : a journal of neurology,
Copied contents to your clipboard!